What top creators are saying about Capricor Therapeutics, Inc.(CAPR)

Surged 390.02% but has concerns about potential fraud, extreme volatility, and high risk. Investors are advised to exercise extreme caution.

Presents a high-risk, high-reward binary event scenario dependent on an upcoming FDA decision for its drug Deremyocel. There are conflicting narratives: a bearish view alleging data manipulation versus the company's bullish presentation of statistically significant trial results that they believe address prior FDA concerns.

The speaker is short the stock, calling it a 'shitty little biotech company' and believes its technology is fraudulent ('it's all cap'), expecting a price collapse on upcoming clinical trial data.

The speaker is short the stock with strong bearish conviction, betting that the upcoming HOPE-III clinical trial data will be negative. A slight delay in the data release reinforces his bearish thesis.

The speaker is extremely bearish, calling it a 'short' and advising to 'sell it all' based on his belief that the company's underlying science is nonsensical.

Speaker is building a short position, potentially via November $4 puts, based on a valuation analysis suggesting the stock could trade down to its cash levels, around $1.80 per share.

Considered a 'good short' as the speaker believes its drug 'doesn't do anything' and expects negative data in two weeks, with a potential downside of ~50% to around $2.14.

Identified as a high-conviction short idea. The speaker is anticipating its HOPE-3 clinical trial will fail, which would be a 'profit extravaganza' for short-sellers.

The speaker is bearish and explicitly states that 'Capper is a short.'

The speaker was extremely critical, highlighting that the FDA rejected their drug and that the stock may be trading on hype from a 'big retail fan base' rather than fundamentals.

The speaker is short the stock and confident the position will be profitable, noting the stock has already declined significantly ('got smoked').

Cited as an example of a flawed cell therapy strategy, with data allegedly showing that 99% of its infused cells are gone from the body within minutes.

Views it as a compelling short candidate due to flawed science, 'fugazi' clinical data, and a belief the FDA will not approve its drug CAP-1002.

Mentioned in a list of biotech stocks without any specific context or opinion, suggesting it is on the speaker's radar but no actionable insight was provided.

Mentioned in a list of biotech stocks that are 'next' for shorting and are predicted to go to zero.